Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
NRG Oncology
Seagen Inc.
AstraZeneca
Daiichi Sankyo
RenJi Hospital
Columbia University
Nagoya University
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Zhujiang Hospital
Fudan University